Radically Optimize Bi, Tri & Multispecific Antibodies to Enhance Target Discovery, Mechanistic Diversity & Clinical Translation to Maximize the Therapeutic Index & Enhance Combinations

Welcome to the 15th World Bispecific Summit

Discover & Optimize the Next Generation of Developable of Bi, Tri - & Multispecific Drugs

As of 2023, more than 10 bispecific antibodies have been successfully approved by the FDA, and more than 100 are currently in clinical trials, highlighting biopharma’s continued investment within bispecific therapeutics.

As we look to the future of bispecific drugs and focus on novel formats and exploring new mechanisms to differentiate from the crowd, the 15th World Bispecific Summit continues to be the industry’s one-stop-shop for all your strategic needs within bi, tri or multi-specifics or even bispecific ADCs or BiTEs.

Drug developers across discovery, preclinical and clinical development are joining forces once more to create an improved foothold in this exciting area of drug discovery and bring better and more efficacious bispecific drugs to patients across different disease indications.

Given the reach bispecific drugs can have, the hunt is on for novel targets that can transform the lives of patients, whether it’s new targets and combinations to improve the safety profile for haematological malignancies, overcoming the immunosuppressive microenvironment within solid tumors, or switching the immune system off in autoimmune disease.

Moving towards more personalized medicine, profiling bispecific candidates preclinically to ensure the developability has never been more important. Although time consuming, the benefits in the reduction of the risk and spend is huge in getting candidates into the clinic. Join this meeting to hear novel ideas and concepts, preclinical data, and clinical lessons to enhance the developability of your bispecific drug.

The 2024 World-Class Speaker Faculty Includes:

Previously Attending Companies Include:

Companies Attending (2)

What Past Attendees Had To Say:

"Engaging science and a variety of strong presentations and discussions highlighting innovative approaches that are being implemented and tested in the rapidly developing field of bispecific"

Eli Lilly

"I was able to gain cutting-edge insights, including an overview, and had the opportunity to engage with leading researchers"

Daiichi Sankyo

"Informative and energizing opportunity to hear about the latest advances in bispecific antibodies from the leaders in the field"


Our 2024 Partners:

Program Partner:


Innovation Partner:

images (1)

Exhibition Partner:


Research Partner: